Adjuvant‐Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination. Issue 17 (8th March 2016)

• Record Type: Journal Article
• Authors: Cheung, Alexander S.; Koshy, Sandeep T.; Stafford, Alexander G.; Bastings, Maartje M. C.; Mooney, David J.
• Is Part Of: Small. Volume 12:Issue 17(2016)
• Page Start: 2321
• Page End: 2333
• Publication Date: 2016-03-08
• Subjects: cancer vaccines -- immunotherapy -- cancer cell vesicles -- drug carriers -- lysate; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.201600061
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract : Targeted subunit vaccines for cancer immunotherapy do not capture tumor antigenic complexity, and approaches employing tumor lysate are often limited by inefficient antigen uptake and presentation, and low immunogenicity. Here, whole cancer cells are processed to generate antigen‐rich, membrane‐enclosed subcellular particles, termed "reduced cancer cells", that reflect the diversity and breadth of the parent cancer cell antigen repertoire, and can be loaded with disparate adjuvant payloads. These vesicular particles enhance the uptake of the adjuvant payload, and potentiate the activation of primary dendritic cells in vitro. Similarly, reduced cancer cell‐associated antigens are more efficiently presented by primary dendritic cells in vitro than their soluble counterparts or lysate control. In mice, vaccination using adjuvant‐loaded reduced cancer cells facilitates the induction of antigen‐specific cellular and humoral immune responses. Taken together, these observations demonstrate that adjuvant‐loaded reduced cancer cells could be utilized in cancer vaccines as an alternative to lysate. Abstract : Immunogenic subcellular vesicular particles that can be used to stimulate antigen‐specific immune responses in vitro and in vivo are generated from whole cancer cells. The particles retain a broad antigen repertoire similar to that of the parent cells, and can be loaded with disparate adjuvant payloads. These particles may represent a superior alternative to lysate, the standard for primary antigen preparations, in various cancer vaccine applications.